Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHEPHERD study of SUL-238 in early untreated Parkinson's disease
2025-524674-42-00Phase 2Authorised
- Sponsor
- Gen Ilac Ve Saglik Urunleri
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing SUL-238 with Placebo (2 arms). Primary endpoint: Change in brain high-energy phosphate metabolites by 31P-MRS at Week 4. Planned start Feb 2026; status: authorised.
02
Drugs
SUL-238
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2025-524674-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524674-42-00.